Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies
Journal of Clinical Medicine · 15.03.2023 · 12 (6) · 2262
DOI: 10.3390/jcm12062262 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 15.03.2023. Verfasst von Chieh-Chen Wu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Healthcare Information and Management, School of Health Technology, Ming Chuan University, Taoyuan 33300, Taiwan. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Previous epidemiological studies have raised the concern that the use of proton pump inhibitors (PPIs) is associated with an increased risk of kidney diseases. To date, no comprehensive meta-analysis has been conducted to assess the association between PPIs and the risk of chronic kidney disease (CKD). Therefore, we conducted a systematic review and meta-analysis to address the association between PPIs and CKD. The primary search was conducted in the most popular databases, such as PubMed, Scopus, and Web of Science. All observational studies evaluated the risk of CKD among PPI users, and non-users were considered for inclusion. Two reviewers conducted data extraction and assessed the risk of bias. Random-effect models were used to calculate pooled effect sizes. A total of 6,829,905 participants from 10 observational studies were included. Compared with non-PPI use, PPI use was significantly associated with an increased risk of CKD (RR 1.72, 95% CI: 1.02–2.87, p = 0.03). This updated meta-analysis showed that PPI was significantly associated with an increased risk of CKD. Association was observed in the same among moderate-quality studies. Until further randomized control trials (RCTs) and biological studies confirm these results, PPI therapy should not stop patients with gastroesophageal reflux disease (GERD). However, caution should be used when prescribing to patients with high-risk kidney disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Healthcare Information and Management, School of Health Technology, Ming Chuan University, Taoyuan 33300, Taiwan.
- Department of Exercise and Health Promotion, College of Kinesiology and Health, Chinese Culture University, Taipei 11114, Taiwan.
- Superintendent Office, Yonghe Cardinal Tien Hospital, New Taipei City 23148, Taiwan.
- Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City 23142, Taiwan.
- Department of Emergency, Min-Sheng General Hospital, Taoyuan 33044, Taiwan.
- Graduate Institute of Injury Prevention and Control, College of Public Health, Taipei Medical University, Taipei 11031, Taiwan.
ORCID-Profile: Chieh-Chen Wu, Woon-Man Kung, Yao-Chin Wang
Zitieren
APA
Wu, C. C., Liao, M. H., Kung, W. M., & Wang, Y. C. (2023). Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies. Journal of Clinical Medicine, 12(6), 2262. https://doi.org/10.3390/jcm12062262
Vancouver
Wu CC, Liao MH, Kung WM, Wang YC. Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies. Journal of Clinical Medicine. 2023;12(6):2262. doi:10.3390/jcm12062262
BibTeX
@article{Wu2023,
author = {Wu, Chieh-Chen and Liao, Mao-Hung and Kung, Woon-Man and Wang, Yao-Chin},
title = {Proton Pump Inhibitors and Risk of Chronic Kidney Disease: Evidence from Observational Studies},
journal = {Journal of Clinical Medicine},
year = {2023},
volume = {12},
number = {6},
pages = {2262},
doi = {10.3390/jcm12062262}
}
EUVIMED